Indeed, molecular classification is recommended in the updated ESGO/ESTRO/ESP guidelines, albeit the fact that serous carcinomas belong to the p53-aberrant group; thus, they are considered as high-risk uterine neoplasms [14,51]. This evidence concerns the gene TP53 and tumor of uterus.